作者
Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen,Hans Prenen
摘要
Reported here are results from the esophageal squamous cell carcinoma (SCC) cohort of a Phase II, non-comparative, basket study, evaluating the anti-tumor activity and safety of FAP-IL2v plus atezolizumab in patients with advanced/metastatic solid tumors (NCT03386721).